Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method comprises the steps of determining an at-risk mentee's behavior and progress in a period of time, determining the mentee's income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior and/or income tax payment during the period of time.

Abstract: Method and systems of automated document processing described herein include activating in sequence a plurality of illumination modules of an illumination source to illuminate a document, where the plurality of illumination modules are located at different positions relative to the document. The document can be imaged each time the document is illuminated by an illumination module to provide a plurality of images. A shadow profile of the document can be obtained based on the plurality of images. One or more of a boundary of the document and presence of a fastener attached to the document can be identified using the shadow profile. Any fasteners present may be removed using a robot arm.

Abstract: A method for treating sleep disorders includes the step of administering to a subject in need therefor a pharmaceutical composition comprising one or more analgesic agents. Also disclosed is a pharmaceutical composition for treating sleep disorders. The pharmaceutical composition comprises one or more analgesic agents and an anti-insomnia agent.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method comprises the steps of determining an at-risk mentee's behavior and progress in a period of time, determining the mentee's income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior and/or income tax payment during the period of time.

Abstract: Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method comprises the steps of determining an at-risk mentee's behavior and progress in a period of time, determining the mentee's income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior and/or income tax payment during the period of time.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: A method for processing information for mentoring service to at-risk people is described. Also describes is a system for implementing the method and a tangible computer readable medium for storing instructions that, when executed by computer processor, causes the computer processor to process information according to the method of the present application.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method comprises the steps of determining an at-risk mentee's behavior and progress in a period of time, determining the mentee's income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior and/or income tax payment during the period of time.

Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.

Abstract: Methods and compositions for reducing frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.